Isometheptene isomer

The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH). The (R)-Isometheptene enantiomer ...

Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

ISOMETHEPTENE ISOMER

The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), 4. The compound of claim 2 , wherein the pharmaceutically acceptable addition salt is selected from mucate and bitartrate.5. The compound of claim 2 , wherein the pharmaceutically acceptable addition salt is selected from mucate and bitartrate.6. The compound of claim 3 , wherein the pharmaceutically acceptable addition salt is selected from mucate and bitartrate.7. The (R)-enantiomeric Isometheptene compound of claim 3 , capable of selectively or specifically binding to Imidazoline receptor type 1 (I).8. The (S)-enantiomeric Isometheptene compound of claim 3 , relatively free of binding to Imidazoline receptor type 1 (I).11. A pure (R)-enantiomeric Isometheptene mucate salt according to in crystal form.12. A composition comprising a purified Isometheptene enantiomer or pharmaceutically acceptable addition salt or hydrochloride thereof; and a nontoxic carrier.13. The composition of claim 10 , comprising a purified (S)-Isometheptene enantiomer or hydrochloride or pharmaceutically acceptable addition salt thereof; and a nontoxic carrier.14. The composition of claim 10 , comprising a purified (R)-Isometheptene enantiomer or a hydrochloride or pharmaceutically acceptable addition salt thereof; and a nontoxic carrier.15. A composition comprising a therapeutic amount of the (S)-Isometheptene enantiomer compound of claim 2 , or a pharmaceutically acceptable addition salt thereof; and a nontoxic carrier.16. A composition comprising a therapeutic amount of the (R)-Isometheptene enantiomer compound of claim 3 , or a pharmaceutically acceptable addition salt thereof; and a nontoxic carrier.17. A composition comprising the (S)-Isometheptene enantiomer mucate salt of ; and a nontoxic carrier.18. A composition comprising the (R)-Isometheptene enantiomer mucate salt of ; and a nontoxic carrier.19. The composition according to claim 10 , wherein the Isometheptene enantiomer ...

COMPOSITIONS AND METHODS FOR INCREASING COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND TREATING ALCOHOLISM

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor. 134-. (canceled)35. An oral composition for treating or reducing alcoholism in a patient comprising a monoamine oxidase B (MAOB) inhibitor selected from selegiline and an aldehyde dehydrogenase (ALDH) inhibitor selected from disulfiram wherein the amount of selegiline is 5 mg to 10 mg per day , and the amount of disulfiram is about 250 mg per day.36. The composition according to claim 35 , wherein the composition is formulated as a capsule claim 35 , or a tablet.37. The composition according to claim 35 , wherein the composition comprises a therapeutically effective single dosage.38. The composition according to claim 35 , wherein the patient is human.39. An oral composition for enhancing patient compliance with regimen for treatment of alcoholism claim 35 , the composition comprising a monoamine oxidase B (MAOB) inhibitor selected from selegiline and an aldehyde dehydrogenase (ALDH) inhibitor selected from disulfiram claim 35 , wherein the amount of selegiline is 5 mg to 10 mg per day claim 35 , and the amount of disulfiram is about 250 mg per day.40. The composition according to claim 39 , wherein the composition is administered as a capsule claim 39 , or a tablet.41. The composition according to claim 39 , wherein the patient is human.42. The composition according to claim 39 , wherein the composition comprises a therapeutically effective single dosage.43. The composition according to or claim 39 , wherein the monoamine oxidase B (MAOB) inhibitor is in pharmaceutically acceptable salt form.44. The composition according to or claim 39 , wherein the aldehyde dehydrogenase (ALDH) inhibitor is in pharmaceutically acceptable salt form.45. A self-administration composition for treatment of alcoholism comprising a ...

Methods and Compositions for Treating Depression using Cyclobenzaprine

The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug. 1. A method for treating depression comprising administering to a human in need of such treatment a pharmaceutical composition comprising cyclobenzaprine in a therapeutically effective amount and a therapeutically effective carrier , wherein such treatment ameliorates or eliminates the depression.2. The method of claim 1 , wherein the amount of cyclobenzaprine administered is less than 5 mg/day.3. The method of claim 2 , wherein the amount of cyclobenzaprine administered is less than 2.5 mg/day.4. The method of claim 1 , wherein the method further comprises administering sequentially or concurrently an antidepressant drug.5. The method of claim 1 , wherein the pharmaceutical composition is administered as an orally dissolving tablet or as a thin film formulation.6. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with psychotherapeutic intervention.7. The method of claim 1 , wherein the pharmaceutical composition is administered at bedtime.8. A pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine in combination with an antidepressant drug.9. The pharmaceutical composition of claim 8 , wherein the amount of cyclobenzaprine is less than 5 mg.10. The pharmaceutical composition of claim 9 , wherein the amount of cyclobenzaprine is less than 2.5 mg.11. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is an orally dissolving tablet or a thin film formulation. This patent application claims priority from provisional patent application Ser. No. 61/449,838, filed Mar. 7, 2011.The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical ...

Compositions and methods for transmucosal absorption

The invention provides compositions and methods for administering compounds for transmucosal absorption. The compositions and methods have a number of surprising pharmacokinetic benefits over oral administration of a compound.

EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol. 1. A pharmaceutical composition comprising a eutectic of mannitol and Cyclobenzaprine HCl.2. The pharmaceutical composition of claim 1 , wherein the eutectic mixture melts at 143.6±3° C.3. The pharmaceutical composition of claim 1 , comprising 60%-90% Cyclobenzaprine HCl and 40%-10% mannitol.4. The pharmaceutical composition of claim 3 , comprising amounts of Cyclobenzaprine HCl and mannitol selected from: 60%±2% Cyclobenzaprine HCl and 40%±2% mannitol claim 3 , 65%±2% Cyclobenzaprine HCl and 35%±2% mannitol claim 3 , 70%±2% Cyclobenzaprine HCl and 30%±2% mannitol claim 3 , 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol claim 3 , 80%±2% Cyclobenzaprine HCl and 20%±2% mannitol claim 3 , 85%±2% Cyclobenzaprine HCl and 15%±2% mannitol claim 3 , and 90%±2% Cyclobenzaprine HCl and 10%±2% mannitol.5. The pharmaceutical composition of claim 4 , comprising 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol.65. The pharmaceutical composition of any one of - claims 1 , wherein the Cyclobenzaprine HCl:mannitol molar ratio is 1.76±0.1.7. (canceled)85. The pharmaceutical composition of any one of - claims 1 , further comprising a basifying agent.9. The pharmaceutical composition of claim 8 , wherein the basifying agent is KHPOor NaHPOor trisodium citrate claim 8 , anhydrous.1011-. (canceled)125. The method of manufacturing a eutectic composition of any one of - claims 1 , comprising mixing Cyclobenzaprine HCl and mannitol or milling Cyclobenzaprine HCl and mannitol.1318-. (canceled)19. The method of claim 12 , wherein the pharmaceutical composition comprises a basifying agent.20. The method of claim 19 , wherein the basifying agent is KHPOor NaHPOor trisodium citrate claim 19 , anhydrous.2122-. (canceled)23. A pharmaceutical composition comprising a eutectic of mannitol and Amitriptyline HCl. ...

Compositions and methods for transmucosal absorption

The disclosure provides compositions and methods for administering therapeutic compounds, specifically cyclobenzaprine or amitryptyline, for transmucosal absorption, wherein the compositions contain a basifying agent in addition to the therapeutic agent. The compositions and methods have a number of surprising pharmacokinetic benefits over oral administration. Methods of treating fibromyalgia in a human subject are also provided.

Radio-and chemo-protective compounds

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-l-thiol. Their use as radio- and chemo-protectors is also described.

anti-CD 154 antibodies and uses thereof

本公开内容涉及具有经修饰的效应子功能的抗人CD154抗体。本公开内容还涉及这些抗人CD154抗体在治疗与CD154激活相关联的状况中的用途，所述与CD154激活相关联的状况例如为移植排斥、炎性状况和疾病、与病毒感染和疾病相关联的功能失调的免疫应答、自身免疫性状况和疾病、变应性状况、动脉粥样硬化状况或者神经变性状况和疾病。本公开内容还涉及这些抗人CD154抗体在移植患者中诱导中枢耐受和造血细胞嵌合中的用途。

Radio-protective and chemo-protective substituted thiols

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate toThe use of these compounds as radio— and chemo—protectors is also described.

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Methods and compositions for treating depression using cyclobenzaprine

【課題】うつ病の処置または予防のための方法、ならびに関連する薬学的組成物を提供すること。【解決手段】本発明は、うつ病の処置または予防のための方法、および関連する薬学的組成物に関する。特に重要であるのは、単独で、または抗うつ薬との組み合わせにおいて、シクロベンザプリンを含む薬学的組成物である。一局面において、本発明は、うつ病を処置する方法であり、上記方法は、このような処置を必要とするヒトに、治療上有効な量のシクロベンザプリンおよび治療上有効なキャリアを含む薬学的組成物を投与する工程を包含し、ここでこのような処置は、上記うつ病を改善または排除する。【選択図】なし

Compositions and methods for transmucosal absorption

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Provided are eutectic formulations comprising mannitol, and either cyclobenzaprine hydrochloride or amitriptyline hydrochloride.

Treatment for cocaine addiction

A novel pharmaceutical composition is provided for the control of stimulant effects, in particular treatment of cocaine addiction, or further to treatment of both cocaine and alcohol dependency, including simultaneous therapeutic dose application or a single dose of a combined therapeutically effective composition of disulfiram and selegiline compounds or pharmaceutically acceptable non-toxic salt thereof.

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Provided are eutectic formulations comprising mannitol, and either cyclobenzaprine hydrochloride or amitriptyline hydrochloride.

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Cyclobenzaprine treatment for sexual dysfunction

The present disclosure provides a pharmaceutical composition comprising therapeutically effective amounts of cyclobenzaprine and one or more agents, and methods of treating and/or preventing sexual dysfunction.

Methods and compositions for treating depression using cyclobenzaprine

The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug.

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Radio-and chemo-protective compounds

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.

Radio-and chemo-protective compounds

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-l-thiol. Their use as radio- and chemo-protectors is also described.

シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤

【課題】シクロベンザプリンＨＣｌおよびマンニトールまたはアミトリプチリンＨＣｌおよびマンニトールの共融物を含む、薬学的組成物およびその製造方法を提供すること。【解決手段】一部の実施形態では、本発明は、マンニトールおよびシクロベンザプリンＨＣｌの共融物を含む組成物を提供する。一部の実施形態では、本発明は、マンニトールおよびアミトリプチリンＨＣｌの共融物を含む組成物を提供する。当業者であれば、これらの組成物が、本明細書記載のものなど、様々な方法での投与に好適であり得ることは理解できるはずである。例えば、組成物は、経口投与（シクロベンザプリンまたはアミトリプチリンが消化管で吸収される場合の投与）または経粘膜吸収（例、舌下、口腔または鼻腔内吸収または吸入による）に適したものであり得る。【選択図】なし

Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral

composições compreendendo ciclobenzaprina ou amitriptilina e seu uso via absorção transmucosa. a presente invenção refere-se a composições e métodos para administração de compostos terapêuticos, especificamente da ciclobenzaprina ou da amitriptilina, para absorção transmucosa, em que as composições contêm um agente alcalinizante além do agente terapêutico. as composições e métodos têm uma série de benefícios farmacocinéticos surpreendentes em comparação com a administração oral. a presente invenção se refere também a métodos de tratamento de fibromialgia em um ser humano.

用经修饰的抗-cd154抗体诱导免疫耐受的方法

本公开内容涉及通过下述方式来在移植期间诱导耐受的方法：向移植受者施用具有经修饰的(例如，选择性地减小的)效应子功能的抗‑CD154抗体，将产生对于供者器官、供者组织或供者细胞具有耐受性的免疫细胞的造血干细胞移植到所述受者中。所述耐受可以是中枢耐受、外周耐受或器官特异性耐受。

Randomization honoring methods to assess the significance of interventions on outcomes in disorders

Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein. In particular, a non-parametric analyzer implementing randomization tests and associated methods for analyzing clinical data is provided. The non-parametric analyzer receives clinical trial data comprising a data structure containing data corresponding to subjects in the clinical trial, where the subjects have been organized into treatment groups, including at least one control group. The non-parametric analyzer generates multiple treatment allocations of the data structure by reorganizing, at random, the subjects along with corresponding data to generate further groups. In some embodiments, the non-parametric analyzer determines the statistical significance based on an overall probability and the multiple allocations of the data structure. The overall probability may be generated via a combination analysis for comparing test statistics between groups of the data structure and the multiple allocations.

Randomization honoring methods to assess the significance of interventions on outcomes in disorders

Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein. In particular, a non-parametric analyzer implementing randomization tests and associated methods for analyzing clinical data is provided. The non-parametric analyzer receives clinical trial data comprising a data structure containing data corresponding to subjects in the clinical trial, where the subjects have been organized into treatment groups, including at least one control group. The non-parametric analyzer generates multiple treatment allocations of the data structure by reorganizing, at random, the subjects along with corresponding data to generate further groups. In some embodiments, the non-parametric analyzer determines the statistical significance based on an overall probability and the multiple allocations of the data structure. The overall probability may be generated via a combination analysis for comparing test statistics between groups of the data structure and the multiple allocations.

Randomization honoring methods to assess the significance of interventions on outcomes in disorders

Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein. In particular, a non-parametric analyzer implementing randomization tests and associated methods for analyzing clinical data is provided. The non-parametric analyzer receives clinical trial data comprising a data structure containing data corresponding to subjects in the clinical trial, where the subjects have been organized into treatment groups, including at least one control group. The non-parametric analyzer generates multiple treatment allocations of the data structure by reorganizing, at random, the subjects along with corresponding data to generate further groups. In some embodiments, the non-parametric analyzer determines the statistical significance based on an overall probability and the multiple allocations of the data structure. The overall probability may be generated via a combination analysis for comparing test statistics between groups of the data structure and the multiple allocations.

Method for treating neurodegenerative dysfunction

A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment. Formula I is: (formula I), wherein: A is a bridge selected from the following radicals: -(CH 2 )m -, -CH=CH-, -(CH 2 ) P - O-, -(CH 2 ) P -S-, -(CH 2 )P-SO 2 -, -(CH 2 ) p -NR 1 - and -SO 2 -NR 2 --, and wherein: m is an integer of from 1 to 3 inclusive; p is an integer selected from 1 and 2; R 1 is selected from the group consisting of hydrogen and C 1 -C 5 alkyl; and R 2 is C 1 -C 5 alkyl; X and Y are independently selected from the group consisting of hydrogen and halogen; R and R' are independently selected from the group consisting of hydrogen and C 1 -C 5 alkyl; n is an integer from 1 to 12 inclusive; and * denotes an asymmetric carbon.

Method for treating neurodegenerative dysfunction

Method for treating neurodegenerative dysfunction

Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients

The present invention concerns methods of treating and/or preventing sexual dysfunction, wherein the sexual dysfunction is associated with one or more mental health conditions, the method using a pharmaceutical composition comprising therapeutically effective amounts of cyclobenzaprine or a pharmaceutically acceptable salt thereof, and potentially one or more additional agents.

Isometheptene isomer

用经修饰的抗-cd154抗体诱导免疫耐受的方法

本公开内容涉及通过下述方式来在移植期间诱导耐受的方法：向移植受者施用具有经修饰的(例如，选择性地减小的)效应子功能的抗‑CD154抗体，将产生对于供者器官、供者组织或供者细胞具有耐受性的免疫细胞的造血干细胞移植到所述受者中。所述耐受可以是中枢耐受、外周耐受或器官特异性耐受。

基于重组痘病毒的抗SARS-CoV-2病毒疫苗

本发明在各个方面涉及包含编码SARS‑CoV‑2病毒蛋白质的核酸的重组痘病毒、生产此类病毒的方法和此类病毒的用途。其中，重组痘病毒非常适合作为抗SARS‑CoV‑2病毒的保护性病毒疫苗。

Isometheptene isomer

Isomero de isometepteno

LA INVENCION SE REFIERE A UN COMPUESTO DE ISOMETEPTENO PURIFICADO QUE COMPRENDE LA ESTRUCTURA SEGUN LA FORMULA (I), O UN CLORHIDRATO, O UNA SAL DE ADICIÓN FARMACEUTICAMENTE ACEPTABLE DEL MISMO. EN PARTICULAR, LA DESCRIPCIÓN SE REFIERE A LA SINTESIS, PURIFICACIÓN Y CARACTERIZACIÓN DE UN CRISTAL DE MUCATO DE ISOMERO 2 DE ISOMETEPTENO, EN DONDE EL ISOMERO 2 DE ISOMETEPTENO SE CARACTERIZA ESTEREOQUIMICAMENTE COMO ENANTIOMERO (R), RESPECTIVAMENTE. LA ACTIVIDAD DEL ENANTIÓMERO (R) DE ISOMETEPTENO INDICA UN LIGANDO SELECTIVO QUE ACTUA DE MANERA CENTRAL SELECTIVO PARA SITIOS DEL RECEPTOR DE IMIDAZOLINA SUBTIPO 1 (II); Y MAS ESPECIFCAMENTE, LA DESCRIPCIÓN PROPORCIONA UNA COMPOSICION ANTIHIPERTENSORA PARA EL TRATAMIENTO DE LA MIGRAÑA Y OTRO DOLOR NEUROVASCULAR O NEUROGENICO DE MOLESTIA ABDOMINAL. EL ISÓMERO 2 O ENANTIOMERO (R) O DE ISOMETEPTENO PUEDE SER UN AGENTE ANTIHIPERTENSOR CON EFECTOS SECUNDARIOS MENORES QUE LA FORMA DE RACEMATO. POR TANTO, SE CREE QUE (R)-ISOMETEPTENO ES EFICAZ FRENTE A CEFALEAS DE TIPO TENSIONAL EPISÓDICAS (ETTH). SE CREE QUE EL ISÓMERO 2 O ENANTIOMERO (R) DE ISOMETEPTENO REDUCE DE MANERA EFICAZ LA TENSION ARTERIAL, USADO SOLO O JUNTO CON OTROS FÁRMACOS QUE MEJORAN CEFALEAS. SE DESCRIBEN METODOS DE SINTESIS Y TRATAMIENTO. EN CUANTO A CRISTALES DE (R)-ISOMETEPTENO SE PRESENTAN DATOS DE CRISTALOGRAFIA DE RAYOS X.

经修饰的tff2多肽

本文描述了经修饰的TFF2多肽、包含这些多肽的组合物和它们用于治疗癌症和炎症的用途。

抗-cd154抗体及其用途

本公开内容涉及具有经修饰的效应子功能的抗人CD154抗体。本公开内容还涉及这些抗人CD154抗体在治疗与CD154激活相关联的状况中的用途，所述与CD154激活相关联的状况例如为移植排斥、炎性状况和疾病、与病毒感染和疾病相关联的功能失调的免疫应答、自身免疫性状况和疾病、变应性状况、动脉粥样硬化状况或者神经变性状况和疾病。本公开内容还涉及这些抗人CD154抗体在移植患者中诱导中枢耐受和造血细胞嵌合中的用途。

Composiciones y métodos de absorción transmucosa

Composiciones y métodos para administrar compuestos por medio de una absorción transmucosa. Las composiciones y los métodos ofrecen numerosos beneficios farmacocinéticos sorprendentes frente a la administración oral de un compuesto. Reivindicación 1: Una composición, caracterizada porque comprende ciclobenzaprina, en donde la composición es adecuada para una absorción transmucosa. Reivindicación 2: Una composición, caracterizada porque comprende ciclobenzaprina y un agente basificante, en donde la composición es adecuada para una absorción transmucosa. Reivindicación 3: Una composición, caracterizada porque comprende amitriptilina, en donde la composición es adecuada para una absorción transmucosa. Reivindicación 45: La composición de la reivindicación 44, caracterizada porque, cuando se administra por absorción transmucosa, la composición da como resultado una Cₘáˣ de ciclobenzaprina mayor o igual a 15 ng/ml por encima del nivel basal de ciclobenzaprina en el individuo inmediatamente antes de la administración. Reivindicación 125: Una composición que comprende ciclobenzaprina para una administración transmucosa, caracterizada porque comprende entre aproximadamente 2 y aproximadamente 20 mg de ciclobenzaprina o una sal de la misma, donde dicha formulación provee una Cₘáˣ de ciclobenzaprina de entre aproximadamente 20 y aproximadamente 200 ng/ml, entre aproximadamente 0,0,05 y aproximadamente 2,5 horas después de la administración, y una concentración mínima en plasma de ciclobenzaprina de entre aproximadamente 1 y aproximadamente 5 ng/ml, entre aproximadamente 22 y aproximadamente 26 horas después de la administración, en donde la composición se administra por cuatro días o más como una administración diaria. Reivindicación 127: Una composición, caracterizada porque comprende amitriptilina para una administración transmucosa que comprende entre aproximadamente 2 y aproximadamente 25 mg de amitriptilina o una sal de la misma, donde dicha formulación provee una Cₘáˣ ...